Bristol-Myers Squibb Co. talked up its commitment to the CTLA-4 checkpoint target, accentuating its strong qualities and track record, while also saying it is "not wedded" to the CTLA-4/PD-1 combination in lung cancer and has lots of options, during its second-quarter earnings call July 27.
The second quarter was another strong one for Bristol and its super-successful PD-1 inhibitor Opdivo (nivolumab), which brought in sales...